Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cepesedan is a veterinary brand name for detomidine hydrochloride injection (10 mg/ml), a **small molecule alpha-2 adrenergic agonist** used as a sedative and mild analgesic to facilitate minor surgical and diagnostic procedures in horses and cattle. It acts by binding to presynaptic and postsynaptic alpha-2 adrenoceptors, inhibiting norepinephrine release to reduce sympathetic activity, thereby inducing sedation, analgesia, and decreased heart rate and blood pressure. Developed for equine and bovine use, it is administered intravenously or intramuscularly and is marketed in regions including Canada, Europe, and Australia.[2][3][9][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cepesedan.